Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Punashi Dutta

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Nature Communications|July 24, 2025
Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker studyAziz Zaanan, Audrey Didelot, Chloé Broudin, et al.
JCO Precision Oncology|September 24, 2025
Using Circulating Tumor DNA-Based Molecular Residual Disease Detection for Postoperative Monitoring in Early-Stage Uterine CancerPeter W Ketch, Carly Bess Scalise, Fernando Recio, et al.
Gynecologic Oncology|January 23, 2024
Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignanciesFernando Recio, Carly Bess Scalise, Paul Loar, et al.
JCO Precision Oncology|July 19, 2023
Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary MalignanciesAlbert Jang, Sree M Lanka, Ellen B Jaeger, et al.
European Urology Oncology|June 30, 2026
Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± PembrolizumabKevin R Reyes, Ryan Zhu, Cameron Herberts, et al.
Scientific Reports|November 28, 2024
Assessment of circulating tumor DNA in patients with locally advanced rectal cancer treated with neoadjuvant therapyChiara Molinari, Giorgia Marisi, George Laliotis, et al.
Annals of Surgery|March 21, 2025
Circulating Tumor DNA Assessment to Predict Risk of Recurrence after Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Observational StudyShogo Takei, Daisuke Kotani, George Laliotis, et al.
JCO Precision Oncology|September 24, 2025
Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell TumorsRebecca Hassoun, Reuben Ben-David, John P Sfakianos, et al.
European Urology Oncology|July 16, 2024
Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder CancerJohn P Sfakianos, Arnab Basu, George Laliotis, et al.
Journal of Hepatology|November 12, 2024
Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinomaChanghoon Yoo, Hyehyun Jeong, Jae Ho Jeong, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Nature Communications|July 24, 2025
Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker studyAziz Zaanan, Audrey Didelot, Chloé Broudin, et al.
JCO Precision Oncology|September 24, 2025
Using Circulating Tumor DNA-Based Molecular Residual Disease Detection for Postoperative Monitoring in Early-Stage Uterine CancerPeter W Ketch, Carly Bess Scalise, Fernando Recio, et al.
Gynecologic Oncology|January 23, 2024
Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignanciesFernando Recio, Carly Bess Scalise, Paul Loar, et al.
JCO Precision Oncology|July 19, 2023
Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary MalignanciesAlbert Jang, Sree M Lanka, Ellen B Jaeger, et al.
European Urology Oncology|June 30, 2026
Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± PembrolizumabKevin R Reyes, Ryan Zhu, Cameron Herberts, et al.
Scientific Reports|November 28, 2024
Assessment of circulating tumor DNA in patients with locally advanced rectal cancer treated with neoadjuvant therapyChiara Molinari, Giorgia Marisi, George Laliotis, et al.
Annals of Surgery|March 21, 2025
Circulating Tumor DNA Assessment to Predict Risk of Recurrence after Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Observational StudyShogo Takei, Daisuke Kotani, George Laliotis, et al.
JCO Precision Oncology|September 24, 2025
Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell TumorsRebecca Hassoun, Reuben Ben-David, John P Sfakianos, et al.
European Urology Oncology|July 16, 2024
Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder CancerJohn P Sfakianos, Arnab Basu, George Laliotis, et al.
Journal of Hepatology|November 12, 2024
Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinomaChanghoon Yoo, Hyehyun Jeong, Jae Ho Jeong, et al.
Pageof 3